Atlas Trials

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

Clinical trial NCT06534411 · COMPLETED

Trial details

NCT number
NCT06534411
Sponsor
Novo Nordisk A/S
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Diabetes Mellitus, Type 2
Start date
2024-11-05
Primary completion
2026-06-02
Enrollment
1023

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.